Thus for instance, dopaminergic functions have been studied in the context of AD-related pathology (Kar et al., 2004; Guzmán-Ramos et al., 2012a; Puzzo and Arancio, 2013; Moreno-Castilla et al., 2016), with key alterations including reduced secretion of dopamine, reduced expression of the dopamine receptor (mainly D2 subtypes) and lower dopamine active transporter (DAT) expression in the hippocampus and frontal cortex (Alkondon and Albuquerque, 2002; Palop and Mucke, 2010), along with reduced dopamine transmission through D1 and D2 receptors (Iqbal et al., 2013). Here, SLC6A3 is linked to Alzheimer disease.